...
首页> 外文期刊>Journal of Translational Medicine >T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy
【24h】

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy

机译:T细胞受体(TCR)转基因CD8淋巴细胞对转化生长因子β(TGFβ)信号不敏感,介导过继细胞治疗动物模型中的优异肿瘤消退

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Tumor antigen-reactive T cells must enter into an immunosuppressive tumor microenvironment, continue to produce cytokine and deliver apoptotic death signals to affect tumor regression. Many tumors produce transforming growth factor beta (TGFβ), which inhibits T cell activation, proliferation and cytotoxicity. In a murine model of adoptive cell therapy, we demonstrate that transgenic Pmel-1 CD8 T cells, rendered insensitive to TGFβ by transduction with a TGFβ dominant negative receptor II (DN), were more effective in mediating regression of established B16 melanoma. Smaller numbers of DN Pmel-1 T cells effectively mediated tumor regression and retained the ability to produce interferon-γ in the tumor microenvironment. These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer.
机译:肿瘤抗原反应性T细胞必须进入免疫抑制性肿瘤微环境,继续产生细胞因子并传递凋亡性死亡信号以影响肿瘤消退。许多肿瘤会产生转化生长因子β(TGFβ),从而抑制T细胞活化,增殖和细胞毒性。在过继细胞疗法的小鼠模型中,我们证明了通过转导TGFβ显性负性受体II(DN)对TGFβ不敏感的转基因Pmel-1 CD8 T细胞在介导已建立的B16黑色素瘤消退中更有效。少量的DN Pmel-1 T细胞有效地介导了肿瘤消退,并保留了在肿瘤微环境中产生干扰素-γ的能力。这些结果支持将这种DN受体纳入癌症过继细胞治疗的临床试验的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号